RESUMEN
INTRODUCTION AND OBJECTIVES: Functional and durable vascular access is needed for adequate hemodialysis. Arteriovenous fistula is preferred over prosthetic grafts or central venous catheters, but it is associated with high rates of primary failure and maturation failure. Preoperative mapping of arm vessels with color Doppler ultrasound (CDU) has been shown to be helpful in achieving better short and long-term outcomes. Unfortunately, is more time-consuming than a physical examination and requires an experienced examiner and special equipment; some authors defend that CDU should not be part of the routine preoperative assessment. We reported our experience in preoperative vessel mapping using color Doppler ultrasound to purpose a vascular access to the surgical team, surveillance of vascular access, and evaluation of main outcomes (primary failure, maturation failure, and patency). METHODS: This is a single-center retrospective study that includes patients who attended a specific appointment for vascular access planning consultation between January 2019 and December 2021. A nephrologist performed the physical exam and vascular mapping and proposed to the vascular surgeon team a specific type and location of vascular access. Patients were followed until one month after the first hemodialysis through functioning vascular access. RESULTS: In this study, 167 patients were evaluated (114 incident patients - chronic kidney disease stage 4 or 5 - and 53 prevalent patients - under hemodialysis through central venous catheter). The vascular accesses proposed by nephrologist were radial-cephalic arteriovenous fistula in 70 patients (41.9%), brachio-cephalic arteriovenous fistula in 50 patients (29.9%), brachio-basilic arteriovenous fistula in 34 patients (20.4%), arteriovenous graft in 8 patients (4.8%) and central venous catheter in 2 patients (1.2%). Vascular access was constructed in 141 patients: distal arteriovenous fistula in 57 patients (40.4%), brachio-cephalic arteriovenous fistula in 54 patients (38.3%), brachio-basilic AVF in 27 patients (19.1%), and arteriovenous graft in 3 patients (2.1%). The created access corresponds to the proposed access in 129 patients (91.5%). Twenty-two (15.6%) primary failures were registered. Distal arteriovenous fistulas and diabetes mellitus were associated with a higher risk of primary failure (OR=3.929 (1.485-10.392), p=0.004; OR=3.867 (1.235-12.113), p=0.014, respectively). The incidence of maturation failure at eight weeks was 4.8%. The primary patency at 6, 12 and 24 months was 76.3%, 70.4% and 49.2%. Primary assisted patency was 84.8% at 6 and 12 months and 81.3% at 24 months. CONCLUSIONS: This study demonstrates that the study of the entire vascular territory performed with color Doppler ultrasound, within a multidisciplinary team of nephrologists and vascular surgeons, is associated with high rates of autologous access and very low rates of primary failure and maturation failure (almost unprecedented in the literature).
Asunto(s)
Derivación Arteriovenosa Quirúrgica , Grupo de Atención al Paciente , Diálisis Renal , Humanos , Diálisis Renal/métodos , Derivación Arteriovenosa Quirúrgica/métodos , Femenino , Masculino , Estudios Retrospectivos , Persona de Mediana Edad , Anciano , Ultrasonografía Doppler en Color , Cuidados Preoperatorios/métodos , Grado de Desobstrucción VascularRESUMEN
OBJECTIVE: The primary objective is to describe the real-life effectiveness and safety of nivolumab treatment in patients with relapsed or refractory classical Hodgkin's lymphoma. The secondary objective is to describe the therapeutic management after nivolumab monotherapy. METHOD: Observational, retrospective, multidisciplinary study including all patients with relapsed or refractory classical Hodgkin's lymphoma treated with nivolumab monotherapy from November 2015 to March 2023. Patient and treatment-related variables were collected. Effectiveness was measured as overall response rate, progression-free survival and overall survival. Safety was measured as percentage of patients with adverse effects and severity. RESULTS: Thirteen patients were included, median age 37.5â¯years (RIQ: 25.3-54.7), 84.6% male. The median number of previous lines of therapy was 3 (RIQ: 2.0-4.5), including autologous hematopoietic stem cell transplantation (84.6%) and brentuximab vedotin (100%). All received nivolumab 3â¯mg/kg/14â¯days, with a median of 11â¯cycles (RIQ: 6.5-20.5) per patient. Median time on treatment was 4.9â¯months (RIQ: 3.0-9.6) and median follow-up time was 9.2â¯months (RIQ: 5.6-32.3). Complete response was achieved by 3 patients (23.1%), partial response by 3 (23.1%), stable disease by 3 (23.1%) and progression by 4 (30.8%). The objective response rate was 46.2%. Median progression-free survival was 23.9â¯months (95%CI: 0-49.1), median overall survival was not reached. At the study cutoff date, five patients had died (38.5%), four were in complete remission without active treatment (30.8%) and four were continuing treatment (30.8%). Adverse events occurred in 76.9% of patients, 44% of severity ≥3, the most frequent being hypothyroidism and hepatotoxicity. One patient discontinued treatment due to pneumonitis, two suffered treatment delays (thrombocytopenia and hypertransaminemia) and one changed the regimen to monthly (pulmonary toxicity). CONCLUSIONS: Nivolumab in the treatment of relapsed or refractory classical Hodgkin's lymphoma has confirmed in the study sample favorable effectiveness data, expressed as objective response rate of 46.2% and clinical benefit of 69.2%. Safety was acceptable, manageable, and consistent with that described in the literature.
RESUMEN
OBJECTIVE: Estimate daily infections of COVID-19 during the first year of the pandemic in the Santiago Metropolitan Region (SRM) in Chile and Chile that are more realistic than those officially registered. METHOD: Retrospective estimate of daily infections from daily data on COVID-19 deaths, a seroprevalence study, and the REMEDID (Retrospective Methodology to Estimate Daily Infections from Deaths) algorithm. RESULTS: In SRM, it is observed that: 1) the maximum peak of infections was more than double that registered in the official statistics; 2) such peak was reached on May 22 (95% CI: 20-24 May), 2022, that is, 24 days before the official date of the peak of infections; and 3) the first estimated contagion took place on January 28, 2020 (95% CI: January 21 to February 16), that is, 36 days before the official date. In Chile, the situation is similar. During the first wave SRM accounted for 70%-76% of those infected in Chile, while from August 2020 onwards it accounted for 36%-39%. CONCLUSIONS: The official records of COVID-19 infections in SRM and Chile underestimated the real number of positives and showed a delay of about a month in the dynamics of infections. This is not an isolated situation, as it is known to have been the case in other countries as well. However, it is important to have reliable estimates for a correct modeling of the spread of the virus.
RESUMEN
Objetivo: Estimar los casos diarios de COVID-19 durante el primer año de pandemia en Santiago Región Metropolitana (SRM) y en Chile con cifras más realistas que las registradas oficialmente. Método: Estimación retrospectiva de los casos diarios a partir de los datos diarios de fallecimientos por COVID-19, un estudio de seroprevalencia y el algoritmo REMEDID (Retrospective Methodology to Estimate Daily Infections from Deaths). Resultados: En SRM se observa que: 1) el pico máximo de contagios fue superior al doble del registrado en las estadísticas oficiales; 2) dicho pico se alcanzó el 22 de mayo de 2020 (IC95%: 20 a 24 de mayo), esto es, 24 días antes de la fecha oficial del pico de contagios; y 3) el primer contagio estimado tuvo lugar el 28 de enero de 2020 (IC95%: 21 de enero a 16 de febrero), esto es, 36 días antes de la fecha oficial. En Chile, la situación es similar. Durante la primera ola, SRM concentró el 70-76% de los infectados de Chile, mientras que a partir de agosto de 2020 solo concentró el 36-39%. Conclusiones: Los registros oficiales de casos de COVID-19 en SRM y Chile infravaloraron el número real de positivos y mostraron un retraso de alrededor de un mes en la dinámica de contagios. Esta no es una situación aislada, ya que se sabe que también ha sido así en otros países. No obstante, es importante disponer de estimaciones fidedignas para una correcta modelización de la expansión del virus.(AU)
Objective: Estimate daily infections of COVID-19 during the first year of the pandemic in the Santiago Metropolitan Region (SRM) in Chile and Chile that are more realistic than those officially registered. Method: Retrospective estimate of daily infections from daily data on COVID-19 deaths, a seroprevalence study, and the REMEDID (Retrospective Methodology to Estimate Daily Infections from Deaths) algorithm. Results: In SRM, it is observed that: 1) the maximum peak of infections was more than double that registered in the official statistics; 2) such peak was reached on May 22 (95% CI: 2024 May), 2022, that is, 24 days before the official date of the peak of infections; and 3) the first estimated contagion took place on January 28, 2020 (95% CI: January 21 to February 16), that is, 36 days before the official date. In Chile, the situation is similar. During the first wave SRM accounted for 70%76% of those infected in Chile, while from August 2020 onwards it accounted for 36%39%. Conclusions: The official records of COVID-19 infections in SRM and Chile underestimated the real number of positives and showed a delay of about a month in the dynamics of infections. This is not an isolated situation, as it is known to have been the case in other countries as well. However, it is important to have reliable estimates for a correct modeling of the spread of the virus.(AU)
Asunto(s)
Humanos , Masculino , Femenino , Incidencia , /epidemiología , /mortalidad , Causas de Muerte , Mortalidad , Chile , Estudios RetrospectivosRESUMEN
INTRODUCTION: Multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) is difficult to control, has high morbidity and mortality, and demands priority public health intervention. In Colombia, MDR/RR-TB has been becoming more widespread annually. Before the COVID-19 pandemic, over an 8-year period, the number of cases of multidrug-resistant tuberculosis in Colombia was close to a thousand cases. Timely identification of the different risk factors for MDR/RR-TB will contribute fundamentally to the systematic management. OBJECTIVE: To determine which risk factors were associated with the presentation of MDR in Colombia between 2013 and 2018. MATERIALS AND METHODS: A retrospective case-control study was carried out, for which the data from the routine surveillance of MDR/events in the country were used. RESULTS: The cases of multidrug-resistant tuberculosis were mainly in young people, Afrodescendants, and males. Of the clinical conditions, comorbidities such as malnutrition, diabetes, and HIV, presence of at least one factor, such as drug dependence, taking immunosuppressive medications, belonging to the black race, afro, and living in an area of high disease burden were risk factors. CONCLUSION: In addition to the diagnosis and timely provision of MDR-TB treatment, it is necessary that public health programs at the local level pay special attention to patients with the identified risk factors.
Introducción: La tuberculosis multirresistente-resistente a la rifampicina (TB-MDR/RR) es difícil de controlar, tiene una alta morbilidad y mortalidad y exige una intervención prioritaria en salud pública. En Colombia, la TB-MDR/RR se ha ido extendiendo cada año. Antes de la pandemia de COVID-19, en un periodo de 8 años, el número de casos de TB-MDR/RR en Colombia se acercaba a los mil. La identificación oportuna de los diferentes factores de riesgo de TB-MDR/RR contribuirá de manera fundamental al manejo sistemático de la enfermedad. Objetivo: Determinar los factores de riesgo que se asociaron a la presentación de la TBMDR/RR en Colombia entre 2013 y 2018. Materiales y métodos: Se realizó un estudio retrospectivo de casos y controles, para el cual se utilizaron los datos de la vigilancia rutinaria de eventos de TB MDR/RR en el país. Resultados: Los casos de TB MDR se presentaron principalmente en jóvenes, afrodescendientes y varones. De las condiciones clínicas, fueron factores de riesgo las comorbilidades como la desnutrición, la diabetes y el VIH, y la presencia de, al menos, un factor como la farmacodependencia, el consumo de medicamentos inmunosupresores, el ser de raza negra o afro y el vivir en una zona del país de alta carga de tuberculosis. Conclusiones: Además del diagnóstico y la provisión oportuna del tratamiento de la TB MDR, es necesario que los programas de salud pública a nivel local presten especial atención a los pacientes con los factores de riesgo identificados.
Asunto(s)
Pandemias , Tuberculosis Resistente a Múltiples Medicamentos , Masculino , Humanos , Adolescente , Estudios de Casos y Controles , Estudios Retrospectivos , Colombia/epidemiología , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/epidemiologíaRESUMEN
Introduction. Multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) is difficult to control, has high morbidity and mortality, and demands priority public health intervention. In Colombia, MDR/RR-TB has been becoming more widespread annually. Before the COVID-19 pandemic, over an 8-year period, the number of cases of multidrug-resistant tuberculosis in Colombia was close to a thousand cases. Timely identification of the different risk factors for MDR/RR-TB will contribute fundamentally to the systematic management. Objective. To determine which risk factors were associated with the presentation of MDR in Colombia between 2013 and 2018. Materials and methods. A retrospective case-control study was carried out, for which the data from the routine surveillance of MDR/events in the country were used. Results. The cases of multidrug-resistant tuberculosis were mainly in young people, Afrodescendants, and males. Of the clinical conditions, comorbidities such as malnutrition, diabetes, and HIV, presence of at least one factor, such as drug dependence, taking immunosuppressive medications, belonging to the black race, afro, and living in an area of high disease burden were risk factors. Conclusion. In addition to the diagnosis and timely provision of MDR-TB treatment, it is necessary that public health programs at the local level pay special attention to patients with the identified risk factors.
Introducción. La tuberculosis multirresistente-resistente a la rifampicina (TB-MDR/RR) es difícil de controlar, tiene una alta morbilidad y mortalidad y exige una intervención prioritaria en salud pública. En Colombia, la TB-MDR/RR se ha ido extendiendo cada año. Antes de la pandemia de COVID-19, en un periodo de 8 años, el número de casos de TB-MDR/RR en Colombia se acercaba a los mil. La identificación oportuna de los diferentes factores de riesgo de TB-MDR/RR contribuirá de manera fundamental al manejo sistemático de la enfermedad. Objetivo. Determinar los factores de riesgo que se asociaron a la presentación de la TB- MDR/RR en Colombia entre 2013 y 2018. Materiales y métodos. Se realizó un estudio retrospectivo de casos y controles, para el cual se utilizaron los datos de la vigilancia rutinaria de eventos de TB MDR/RR en el país. Resultados. Los casos de TB MDR se presentaron principalmente en jóvenes, afrodescendientes y varones. De las condiciones clínicas, fueron factores de riesgo las comorbilidades como la desnutrición, la diabetes y el VIH, y la presencia de, al menos, un factor como la farmacodependencia, el consumo de medicamentos inmunosupresores, el ser de raza negra o afro y el vivir en una zona del país de alta carga de tuberculosis. Conclusiones. Además del diagnóstico y la provisión oportuna del tratamiento de la TB MDR, es necesario que los programas de salud pública a nivel local presten especial atención a los pacientes con los factores de riesgo identificados.
Asunto(s)
Tuberculosis , Estudios de Casos y Controles , Comorbilidad , Estudios Retrospectivos , Factores de Riesgo , Resistencia a Múltiples Medicamentos , Población NegraRESUMEN
Objetivos: Describir la frecuencia de la respuesta clínica y patológica, entre los diferentes subtipos moleculares de cáncer de mama, en pacientes que previamente recibieron quimioterapia neoadyuvante. Materiales y métodos: Cohorte retrospectiva, descriptiva. Se incluyeron mujeres mayores de 18 años, con diagnóstico histológico de carcinoma invasivo de mama, en estadios IIA, IIB, IIIA, IIIB y IIIC, con clasificación por subtipos moleculares, que hubieran recibido quimioterapia neoadyuvante, atendidas en una clínica de alto nivel de complejidad localizada en Medellín (Colombia), entre el 1 de julio de 2017 y el 30 de julio de 2019. Las variables recolectadas fueron edad, estadio clínico, características histológicas, clasificación molecular y la respuesta clínica y patológica completa por subtipo molecular. Se realizó análisis descriptivo. Resultados: 255 pacientes cumplieron con los criterios de inclusión. La edad media fue de 55,2 años; los estadios clínicos con mayor prevalencia fueron IIIB (28,6 %) y IIB (26,3 %), respecto al grado histológico, los más frecuentes fueron grado 3 (48,2 %) y 2 (37,3 %). La frecuencia por subtipos moleculares fue: luminal A (10,2 %), luminal B HER2 negativo (39,6 %), triple negativo (23,1 %), luminal B HER2 positivo (13,7 %), y HER2 puro (13,3 %). La respuesta clínica completa posquimioterapia por subtipo molecular fue: luminal A (26,9 %), luminal B HER2 negativo (37,6 %), luminal B HER2 positivo (48,6 %), HER2 puro (41,2 %), triple negativo (45,8 %); se logró respuesta patológica completa por subtipo molecular, así: luminal A (19,2 %), luminal B HER2 negativo (32,7 %), luminal B HER2 positivo (54,3 %), HER2 puro (50 %), triple negativo (42,4 %). Conclusiones: En la práctica clínica, la clasificación por subtipos moleculares en cáncer de mama permite hacer una aproximación a la respuesta de la quimioterapia neoadyuvante. Se requieren estudios prospectivos en la región para determinar la capacidad predictiva de la respuesta patológica completa respecto a la sobrevida global y libre de enfermedad.
Objectives: To describe the frequency of clinical and pathological response in different molecular subtypes of breast cancer, in patients receiving prior neoadjuvant chemotherapy. Materials and methods: Descriptive retrospective cohort. The study population consisted of women 18 years of age and older with a histological diagnosis of invasive breast cancer stages IIA, IIB, IIIA, IIIB and IIIC, with a classification by molecular subtypes, who had received prior neoadjuvant chemotherapy, seen at a high complexity clinic in Medellin (Colombia), between July 1, 2017, and July 30, 2019. We measured age clinical stage, histological characteristics, molecular classification, and complete clinical and pathological responses by molecular subtype. A descriptive analysis was conducted. Results: Overall, 255 patients met the inclusion criteria. Mean age was 55.2 years; the clinical stages with the highest prevalence were IIIB (28.6 %) and IIB (26.3 %), and the most frequent by histologic grading were grades 3 (48.2 %) and 2 (37.3 %). Frequency by molecular types was as follows: luminal A (10.2 %), HER2-negative luminal B (39.6 %), triple-negative (23.1%), HER2-positive luminal B (13.7 %), and pure HER2 (13.3 %). Complete clinical response following chemotherapy, by molecular type, was as follows: luminal A (26.9 %), HER2-negative luminal B (37.6 %), HER2-positive luminal B (48.6 %), pure HER2 (41.2 %), triple-negative (45.8 %). Complete pathological response by molecular subtype was achieved in the luminal A (19.2 %), HER2-negative luminal B (32.7 %), HER2-positive luminal B (54.3 %), pure HER2 (50 %) and triple-negative (42.4 %) subtypes. Conclusions: In clinical practice, breast cancer classification by molecular subtypes is a means to approach the assess the to neoadjuvant chemotherapy. Se requieren estudios prospectivos en la región para determinar la capacidad predictiva de la respuesta patológica completa respecto a la sobrevida global y libre de enfermedad.
Asunto(s)
Humanos , Femenino , ColombiaRESUMEN
Existen controversias en la definición de la displasia broncopulmonar, siendo las más utilizadas el requerimiento de O2 durante 28 días o a las 36 semanas de edad gestacional corregida (EGC). Nuestro objetivo fue determinar la incidencia y características clínicas de los prematuros nacidos antes de las 32 semanas (RNP≤ 32s) con requerimiento de O2 a los 28 días de vida (DBP28d) y a las 36 semanas de EGC (DBP36s) en una unidad neonatal de Santiago, Chile, entre los años 2012 y 2019. Es un estudio descriptivo, retrospectivo con componente analítico. La población estudiada incluyó 535 RNP≤ 32s, vivos a las 36 semanas o dados de alta después de las 34 semanas de EGC. De los 242 prematuros DBP28d, 203 (83,88%) fueron DBP36s; 16 de los 242 (6%) requirió O2 durante menos de 28 días consecutivos, de los cuales 7, aún lo requerían a las 36 semanas. Los predictores de DBP36s fueron: sexo masculino (OR 2,42, IC del 95%: 1,24-4,69), peso al nacer (OR 1, IC del 95%: 0,99-1), edad gestacional (OR 0,75, IC del 95%: 0,57-0,97), APGAR a los 5 min, (OR 0,01, IC del 95%: 0,003-0,05), el requerimiento de presión positiva continua o cánula nasal de alto flujo (OR 1,1, IC del 95%: 1,04-1,17) y días de ventilación mecánica invasiva (OR 1,1,95% IC: 1-1,2). Conclusiones: No encontramos una diferencia significativa en la incidencia de DBP entre las definiciones de DBP28d y DBP36s; y la mayoría de los RNP< 32s con diagnóstico de DBP36s se pudieron identificar a los 28 días de vida.
Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease in premature newborns. It is commonly defined as a need for supplemental O2 for 28 days or at 36 weeks postmenstrual age (PMA) (BPD36w). Our objective was to determine the incidence and clinical characteristics of premature neonates born at less than 32 weeks (PNB< 32w) with O2 requirement at 28 days of life (DBP28d) and DBP36w in a neonatal unit of Santiago, Chile, between 2012 and 2019. This is a descriptive, retrospective study with an analytical component. The study population included 535 PNB< 32w, alive at 36 weeks or discharged after 34 PMA. Of the 242 premature BPD28d, 203 (83,88%) were BPD36w; 16 (6%) required O2 for less than 28 consecutive days, of which 7 still required it at 36 weeks. The predictors of BPD36w were: male (OR 2.42, 95% CI: 1.24-4.69), birth weight (OR 1, 95% CI: 0.99-1), gestational age (OR 0.75, 95% CI: 0.57-0.97), APGAR at 5 min, (OR 0.01, 95% CI: 0.003-0.05), continuous positive pressure or high-flow nasal cannula requirement (OR 1.1, 95% CI: 1.04-1.17) and days of invasive mechanical ventilation (OR 1.1, 95% CI: 1-1.2). Conclusions: We did not find a significant difference in the incidence of BPD between the definitions of BPD28d and BPD36s; and the majority of PNB < 32w diagnosed with BPD36w can be identified at 28 days of life.
Asunto(s)
Humanos , Recién Nacido , Displasia Broncopulmonar/epidemiología , Terapia por Inhalación de Oxígeno , Respiración Artificial , Displasia Broncopulmonar/terapia , Chile , Incidencia , Estudios Retrospectivos , Análisis de VarianzaRESUMEN
ABSTRACT Objectives: to analyze the incidence of preventable adverse events related to health care in adult patients admitted to public hospitals in Brazil. Methods: observational, analytical, retrospective study based on medical records review. Results: medical records from 370 patients were evaluated, 58 of whom had at least one adverse event. The incidence of adverse events corresponded to 15.7%. Adverse events were predominantly related to healthcare-related infection (47.1%) and procedures (24.5%). Regarding the adverse event severity, 13.7% were considered mild, 51.0% moderate, and 35.3% severe. 99% of adverse events were classified as preventable. Patients admitted to the emergency room had a 3.73 times higher risk for adverse events. Conclusions: this study's results indicate a high incidence of avoidable adverse events and highlight the need for interventions in care practice.
RESUMEN Objetivos: analizar la incidencia de eventos adversos evitables relacionados al cuidado de la salud en pacientes adultos internados en hospitales públicos brasileños. Métodos: estudio observacional, analítico, retrospectivo, basado en la revisión de historias clínicas. Resultados: se evaluaron las historias clínicas de 370 pacientes, 58 de los cuales sufrieron al menos un evento adverso. La incidencia de eventos adversos correspondió al 15,7%. Los eventos adversos estaban relacionados, principalmente, con: infecciones por asistencia sanitaria (47,1%) y procedimientos (24,5%). Respecto a la gravedad de los eventos adversos, el 13,7% era leve, el 51%, moderado y el 35,3%, grave. Se clasificó como evitable el 99% de los eventos adversos. Los pacientes ingresados en urgencias presentaron un riesgo 3,73 veces mayor de aparición de eventos adversos. Conclusiones: los resultados de este estudio señalan una incidencia elevada de eventos adversos evitables y resaltan la necesidad de intervenciones en la práctica asistencial.
RESUMO Objetivos: analisar a incidência de eventos adversos evitáveis relacionados ao cuidado em saúde em pacientes adultos internados em hospitais públicos brasileiros. Métodos: estudo observacional, analítico, de corte retrospectivo, baseado na revisão de prontuários. Resultados: avaliaram-se prontuários de 370 pacientes, dos quais 58 sofreram pelo menos um evento adverso. A incidência de eventos adversos correspondeu a 15,7%. Os eventos adversos foram vinculados: à infecção relacionada à assistência à saúde (47,1%) e a procedimentos (24,5%), predominantemente. No que tange à gravidade dos eventos adversos, averiguou-se que 13,7% foram considerados leves, 51,0%, moderados e 35,3%, graves. Classificou-se como evitáveis 99% dos eventos adversos. Pacientes internados em caráter de urgência apresentaram risco 3,73 vezes maior para a ocorrência de um evento adverso. Conclusões: os resultados deste estudo apontam elevada incidência de eventos adversos evitáveis e contribuem para evidenciar a necessidade de intervenções na prática assistencial.
RESUMEN
La enfermedad pulmonar avanzada (EPAV) es la principal causa de morbimortalidad en pacientes con Fibrosis Quística (FQ). Objetivo: describir características clínicas de pacientes con FQ con EPAV y mortalidad en el seguimiento. Método: Estudio descriptivo, retrospectivo de pacientes con FQ y EPAV: VEF1 4 años de vida. Un 75% era portador de infección crónica por Pseudomonas. Un 68% era dependiente de oxígeno y un 18% de ventilación mecánica no invasiva. El 70 % tuvo 2 o más hospitalizaciones el último año de seguimiento. De 27 pacientes derivados a trasplante, 7 se trasplantaron, 3 fallecieron en lista para trasplante, 9 presentaron alguna contraindicación: 4 de ellos por desnutrición y 5 por mala adherencia y escasa red de apoyo. En el seguimiento un 32% (n = 14) falleció, 93% de causa respiratoria. Conclusión: Un 39% de los pacientes tenían EPAV cuyo diagnóstico de FQ en promedio fue a los 11,2 años (SD ± 13 a). Las barreras de ingreso a lista para trasplante fueron: desnutrición, mala adherencia y falta de red de apoyo. Esta es una población con una elevada mortalidad.
Advanced cystic fibrosis lung disease (ACFLD) is the leading cause of morbidity and mortality in patients with Cystic Fibrosis (CF). Objective: to describe clinical characteristics of patients with CF with ACFLD and mortality during follow-up. Method: Descriptive, retrospective study of patients with CF and ACFLD: FEVi < 40%, oxygen dependent, and/or referred to a lung transplantprogram. Clinical, microbiological, functional, genetic and mortality characteristics were collected. Results: Of 111 controlled patients, 39% met criteria for ACFLD. 52% were men and the mean age was 29,8 years- old. The average BMI was 19.9 kg/m2, 72% had pancreatic insufficiency and 87% had a genetic study, being the DF508 mutation the most frequent (67%). The average age of diagnosis was 11.2 years (SD ± 13 years), being in 54,5% over the age of 4 years. 75% had chronic Pseudomonas infection. 68% were oxygen dependent and 18% on noninvasive mechanical ventilation. In the last year of follow-up 70% had 2 or more hospitalizations. Of 27 patients who have been referred for transplantation, 7 underwent lung transplantation, 3 died waiting on the transplant list, 9 had contraindications: 4 due to malnutrition and 5 to poor adherence and poor support network. 32% (n = 14) of the ACFLD patients died, 93% due to respiratory causes. Conclusion: 39% of the patients had ACFLD. The average age for CF diagnosis was 11.2 years (SD ± 13 years) Barriers to entering the transplant list are: malnutrition, poor adherence, and lack of a support network. This is a population with a high mortality.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Adulto Joven , Fibrosis Quística/fisiopatología , Fibrosis Quística/mortalidad , Comorbilidad , Análisis de Supervivencia , Estudios Retrospectivos , Análisis de Varianza , Estudios de Seguimiento , Trasplante de Pulmón , Fibrosis Quística/cirugía , Fibrosis Quística/diagnóstico , Fibrosis Quística/microbiología , DesnutriciónRESUMEN
Resumen En marzo del año 2020, se declaró una pandemia de características mundiales, por un virus, que genera deterioro importante a nivel sistémico, SARS -CoV-2, con la enfermedad COVID-19. El deterioro funcional de quienes sufren secuelas post COVID-19 ha llevado a los profesionales de la rehabilitación a buscar formas eficientes de intervenir. Este estudio, descriptivo y retrospectivo, evaluó los efectos de un programa de rehabilitación remoto de 6 semanas, en 39 pacientes dados de alta de COVID-19, de un Centro de Salud Familiar (CESFAM) de la Comuna de El Bosque, Santiago, Chile, entre julio y diciembre del año 2020, analizando la capacidad física con el test 1 minuto sentado-de pie y disnea con escala de Borg modificada. Los resultados mostraron cambios estadísticamente significativos en la capacidad física y disnea de los pacientes intervenidos. Es necesario estudiar los beneficios de intervenciones específicas para esta población, y su impacto a largo plazo, entendiendo que convivimos con una nueva enfermedad, un COVID-19 prolongado, que incluso en cuadros leves está dejando secuelas funcionales importantes.
In March 2020, a pandemic of global characteristics was declared, due to a virus, which generates significant deterioration at the systemic level, SARS -CoV-2, with the COVID-19 disease. The functional deterioration of those suffering from post-COVID-19 sequelae has led rehabilitation professionals to look for efficient ways to intervene. This study, descriptive and retrospective, evaluated the effects of a 6-week remote rehabilitation program, in 39 patients discharged from COVID-19, from a Family Health Center in the Commune of El Bosque, Santiago, Chile, between July and December 2020, analyzing physical capacity with the 1 minute sitting-standing test and dyspnea with modified Borg's scale. The results showed statistically significant changes in the physical capacity and dyspnea of the operated patients. It is necessary to study the benefits of specific interventions for this population, and their long-term impact, understanding that we live with a new disease, a prolonged COVID, which even in mild cases is leaving important functional sequelae.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Adulto Joven , Atención Primaria de Salud , Disnea/rehabilitación , Telerrehabilitación/métodos , COVID-19/rehabilitación , Medicina Física y Rehabilitación , Evaluación de Programas y Proyectos de Salud , Chile , Aptitud Física , Salud de la Familia , Estudios Retrospectivos , COVID-19/complicacionesRESUMEN
INTRODUCTION: The sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking. METHODS: A retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (nâ¯=â¯231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (nâ¯=â¯10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment. RESULTS: Overall SVR was 98.8% (95% CI 97.35-100%). Only three patients did not achieve SVR, two of whom had cirrhosis and a history of previous treatment with peg-IFN. Of the subgroups analyzed, all the patients with HIV coinfection, three patients with genotype 3, and the patients treated with the SOF/VEL/RBV combination achieved SVR. The subgroups with the lower success rates were patients that were treatment-experienced (96.8%) and patients with F1 fibrosis (95.5%). The most frequent adverse events were fatigue, headache, and insomnia. No serious adverse events were reported. CONCLUSION: Treatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies.
Asunto(s)
Hepatitis C Crónica , Hepatitis C , Antivirales/efectos adversos , Carbamatos , Genotipo , Hepatitis C/tratamiento farmacológico , Hepatitis C Crónica/tratamiento farmacológico , Compuestos Heterocíclicos de 4 o más Anillos , Humanos , México , Estudios Retrospectivos , Sofosbuvir/efectos adversosRESUMEN
Background: It is essential that the dentist understand the positional variations of the mental foramen to perform different types of dental procedures. This study was conducted to identify the position of the mental foramen among the Saudi population of Al Hasa. Material and Methods: According to the selection criteria of 200 CBCT images, 101 images were selected. The selected images were categorized into five groups with respect to patient age. Each image was evaluated from both sides of the mandible and then recorded in six classes (position I-VI) according to the horizontal position and three classes in the vertical position. Results: In the Saudi Al Hasa population, Type 4 (at the level of 2ndpremolar) was the most common location for mental foramen in the horizontal direction, on the right side (n= 41; 40.6%) and on the left side (n=44; 43.6%). Mental foramen was found in the vertical location, Type 3 (below the apex of 1st and 2nd premolars) was found in the right side (n= 54; 53.5%) and left side (n=56; 55.4%). The position of mental foramen is not constant and changes according to gender and ethnicity. This warrants dentists to evaluate patients individually. Conclusion: Even though the present study was done with a small sample of patients it provides a picture about approximate location of mental foramen among the target group of a population.
Antecedentes: Es esencial que el dentista comprenda las variaciones posicionales del agujero mentoniano para realizar diferentes tipos de procedimientos dentales. Este estudio se realizó para identificar la posición del foramen mental entre la población saudita de Alhasa. Material y Métodos: De acuerdo con los criterios de selección de 200 imágenes CBCT, se seleccionaron 101 imágenes. Las imágenes seleccionadas se categorizaron en cinco grupos con respecto a la edad del paciente. Cada imagen se evaluó desde ambos lados de la mandíbula y luego se registró en seis clases (posición I-VI) según la posición horizontal y tres clases en la posición vertical. Resultados: En la población saudita de Al Hasa, el tipo 4 (al nivel del segundo premolar) fue la ubicación más común para el foramen mental en la dirección horizontal, en el lado derecho (n = 41; 40,6%) y en el lado izquierdo (n = 44; 43,6%). El foramen mental se encontró en la ubicación vertical, el Tipo 3 (debajo del ápice del 1er y 2do premolares) se encontró en el lado derecho (n = 54; 53,5%) y el lado izquierdo (n = 56; 55,4%). La posición del foramen mental no es constante y cambia según el género y la etnia. Esto justifica que los dentistas evalúen a los pacientes individualmente. Conclusión: Aunque el presente estudio se realizó con una pequeña muestra de pacientes, proporciona una imagen sobre la ubicación aproximada del foramen mental entre el grupo objetivo de una población.
Asunto(s)
Humanos , Masculino , Femenino , Tomografía Computarizada de Haz Cónico/métodos , Foramen Mental , Mandíbula/diagnóstico por imagen , Arabia Saudita , Implantes Dentales , Estudios RetrospectivosRESUMEN
OBJECTIVE: To identify factors associated with the risk of death in adolescent and adult inpatients with laboratory-positive (reverse-transcription polymerase chain reaction) influenza in Mexico during consecutive influenza seasons (2018-2020). METHODS: A retrospective cohort study used national surveillance system data, enrolling 3.422 individuals. The association between various risk factors and 30-day in-hospital lethality were evaluated through risk ratios (RRs) and 95% confidence intervals (CIs). RESULTS: The lethality rate was 18.1%. Flu vaccination history (RR=0.56, 95% CI 0.42-0.78), early antiviral drug administration (≤2 days from symptom onset [reference ≥5 days], RR=0.68, 95% CI 0.58-0.81), and a history of asthma (RR=0.66, 95% CI 0.47-0.95) showed protective effects against influenza-attributable death. Mechanical ventilator support produced the highest increase in death risk (RR=3.31, 95% CI 2.89-3.79). Male sex, older age, AH1N1 subtype, and other chronic diseases were also associated with fatal in-hospital influenza-related outcomes. CONCLUSIONS: Our findings highlight the major relevance of promoting immunization in high-risk individuals, together with ensuring early and effective antiviral management in suspected influenza cases.
Asunto(s)
Gripe Humana , Adolescente , Adulto , Anciano , Hospitales , Humanos , Gripe Humana/epidemiología , Laboratorios , Masculino , Estudios Retrospectivos , Factores de RiesgoRESUMEN
RESUMEN El artículo aborda uno de los elementos metodológicos de usual declaración en los proyectos de investigación: el carácter retrospectivo o prospectivo de los estudios. Se propone utilizar como criterio de clasificación, para considerar si un estudio es de un tipo o del otro, la relación que se establece entre el momento en que se diseña la investigación, por una parte, y el momento de la ocurrencia del hecho que se pretende investigar, por la otra. A partir de este criterio, se fundamenta que tanto los estudios de casos y controles como los estudios de cohortes pueden ser realizados retrospectivamente o de forma prospectiva.
ABSTRACT The article addresses one of the methodological elements commonly declared in research projects: the retrospective or prospective nature of the studies. It is proposed to use as a classification criterion, to consider whether a study is of one type or the other, the relationship established between the moment in which the investigation is designed, on the one hand, and the moment of the occurrence of the fact that is pretends to investigate, on the other. Based on this criterion, it is based that both case-control studies and cohort studies can be carried out retrospectively or prospectively.
RESUMEN
El trasplante de pulmón (TP) es una opción para pacientes pediátricos con enfermedades pulmonares terminales. OBJETIVO: Evaluar resultados y sobrevida de pacientes pediátricos trasplantados de pulmón. MÉTODOS: Análisis retrospectivo de registros clínicos de pacientes TP ≤ 15 años de Clínica Las Condes. Se analizaron datos demográficos, tipo de trasplante, función pulmonar basal y post trasplante, complicaciones precoces y tardías y sobrevida. RESULTADOS: Nueve pacientes < 15 años de edad se han trasplantado. La edad promedio fue 12,7 años. La principal indicación fue fibrosis quística (7 pacientes). El IMC promedio fue de 17,6 y todos estaban con oxígeno domiciliario. El 77% utilizó soporte extracorpóreo intraoperatorio. Las principales complicaciones precoces fueron hemorragia y la disfunción primaria de injerto mientras que las tardías fueron principalmente las infecciones y la disfunción crónica de injerto. Cuatro pacientes han fallecido y la sobrevida a dos años fue de 85%. El trasplante les permitió una reinserción escolar y 3 lograron completar estudios universitarios. CONCLUSIÓN: El trasplante pulmonar es una alternativa para niños con enfermedades pulmonares avanzadas mejorando su sobrevida y calidad de vida.
Lung transplantation (TP) is a treatment option in children with terminal lung diseases. OBJECTIVE: To evaluate the results and survival of pediatrics lung transplant patients. METHODS: Retrospective analysis of clinical records of lung transplantation of patients ≤ 15 years from Clínica Las Condes, Santiago, Chile. Demographic data, type of transplant, baseline and post transplant lung function, early and late complications and survival rate were analyzed. RESULTS: Nine patients ≤ 15 years-old were transplanted. The average age at transplant was 12.7 years. The main indication was cystic fibrosis (7 patients). The average BMI was 17.6 and all the patients were with home oxygen therapy. 77% used extracorporeal intraoperative support. Average baseline FEV1 was 25.2% with progressive improvement in FEV1 of 77% in the first year. The main early complications were hemorrhage and primary graft dysfunction, while late complications were infections and chronic graft dysfunction. Four patients have died and the estimated 2 years survival was 85%. They achieved school reinsertion and three managed to complete university studies. CONCLUSION: Lung transplantation is an alternative for children with advanced lung diseases improving their survival and quality of life.
Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Trasplante de Pulmón/estadística & datos numéricos , Enfermedades Pulmonares/cirugía , Pediatría , Bronquiolitis Obliterante , Oxigenación por Membrana Extracorpórea , Análisis de Supervivencia , Chile , Estudios Retrospectivos , Estudios de Seguimiento , Trasplante de Pulmón/efectos adversos , Trasplante de Pulmón/mortalidad , Resultado del Tratamiento , Hemorragia Posoperatoria/etiología , Fibrosis Quística , Disfunción Primaria del Injerto/etiología , Hipertensión Pulmonar , Enfermedades Pulmonares/mortalidadRESUMEN
OBJETIVO: Realizar una caracterización clínica y por imágenes a pacientes hospitalizados por COVID-19 y analizar si existen predictores de riesgo asociados con una mayor gravedad. MÉTODO: Estudio observacional, retrospectivo. Se incluyeron pacientes hospitalizados con COVID-19, entre abril y julio de 2020. Se registraron datos demográficos, comorbilidades, exámenes de laboratorio, tipo de compromiso en tomografía computada (TC) de tórax, terapias recibidas y tipo de soporte respiratorio. En el análisis estadístico para identificar factores de riesgo se utilizó test χ2 de Pearson o test de Fisher para comparar variables categóricas y test de Mann-Whitney para comparar variables continuas. RESULTADOS: Se analizaron 164 pacientes. La mediana de edad fue de 57 años (rango 21 a 89). 111 pacientes (68%) de género masculino y mediana de 7 días de síntomas previo al ingreso (rango 1 a 23). 68 pacientes (41%) tienen obesidad (significativamente mayor en pacientes < 60 años, p = 0,026), 56 (34%) hipertensión arterial (HTA) y 43 (26%) diabetes. El patrón predominante en la TC de ingreso fue de vidrio esmerilado (VE) con "crazy paving" (35%) y luego VE puro (28%). Como indicador de gravedad se tomó en cuenta el tipo de soporte ventilatorio requerido: 51 pacientes (31%) requieren soporte ventilatorio no invasivo (cánula nasal de alto flujo o VMNI) y 19 (11%) ventilación invasiva (VMI). Las variables predictoras de gravedad, estadísticamente significativas, fueron: HTA (p = 0,001), Diabetes Mellitus (p = 0,001) y Obesidad. (p = 0,002). CONCLUSIONES: Los pacientes hospitalizados por COVID 19 con mayor riesgo de evolución tórpida, del punto de vista respiratorio, fueron los pacientes obesos, hipertensos y diabéticos.
OBJECTIVE: To perform a clinical and imaging characterization in patients hospitalized for COVID-19 and to analyze whether there are risk predictors associated with greater severity of the condition. METHOD: Observational, retrospective study. Patients hospitalized with COVID-19 were included between April and July 2020. Demographic data, comorbidities, laboratory tests, tomographic pattern in thorax tomography (TC), therapies received, and type of respiratory support were recorded. In the statistical analysis to identify risk factors, we used Pearson's χ2 test or Fisher's test to compare categorical variables and Mann-Whitney test to compare continuous variables. RESULTS: 164 patients were analyzed. Median age was 57 years (21 to 89). 111 patients (68%) were male and a median of 7 days of symptoms prior to admission (1 to 23). 68 patients (41%) have obesity (significantly higher in patients < 60 years, p = 0.026), 56 (34%) arterial hypertension (HT) and 43 (26%) with diabetes mellitus. The predominant pattern in the admission CT scan was ground glass opacity (GGO) with "crazy paving" (35%) and then pure GGO (28%). Type of ventilatory support required was considered as an indicator of severity. 51 patients (31%) require non-invasive ventilatory support (high-flow nasal cannula or NIMV) and 19 (11%) invasive ventilation (IMV). The statistically significant predictor variables of severity were HT (p = 0.001), Diabetes Mellitus (p = 0.001) and Obesity. (p = 0.002). CONCLUSIONS: Patients hospitalized for COVID 19 with the highest risk of respiratory torpid evolution were obese, hypertensive and diabetic patients
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Adulto Joven , COVID-19/diagnóstico , COVID-19/epidemiología , Respiración Artificial , Tomografía Computarizada por Rayos X , Comorbilidad , Estudios Retrospectivos , Factores de Riesgo , Corticoesteroides/uso terapéutico , Diabetes Mellitus/epidemiología , Prueba de COVID-19 , COVID-19/terapia , Hospitalización/estadística & datos numéricos , Hipertensión/epidemiología , Obesidad/epidemiologíaRESUMEN
INTRODUCTION: The sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking. METHODS: A retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (n = 231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (n = 10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment. RESULTS: Overall SVR was 98.8% (95% CI 97.35-100%). Only three patients did not achieve SVR, two of whom had cirrhosis and a history of previous treatment with peg-IFN. Of the subgroups analyzed, all the patients with HIV coinfection, three patients with genotype 3, and the patients treated with the SOF/VEL/RBV combination achieved SVR. The subgroups with the lower success rates were patients that were treatment-experienced (96.8%) and patients with F1 fibrosis (95.5%). The most frequent adverse events were fatigue, headache, and insomnia. No serious adverse events were reported. CONCLUSION: Treatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies.
RESUMEN
Objetivo Identificar los factores asociados a riesgo de muerte en pacientes adolescentes y adultos hospitalizados con gripe confirmada en laboratorio (reacción en cadena de la polimerasa con transcriptasa inversa) en México durante temporadas consecutivas de gripe (2018-2020). Pacientes y métodos Estudio de cohorte retrospectivo en el que se utilizaron datos del sistema de vigilancia nacional con 3.422 sujetos inscritos. Se evaluó la asociación entre el riesgo a la exposición y el riesgo de letalidad hospitalaria durante 30 días mediante el estudio de los riesgos relativos (RR) y los intervalos de confianza (IC) del 95%. Resultados La tasa de letalidad fue del 18,1%. Los antecedentes de vacunación frente a la gripe (RR = 0,56; IC 95%: 0,42-0,78), la administración de fármacos antivirales (≤ dos días desde la aparición de los síntomas [referencia: ≥ 5 días]; RR = 0,68; IC 95%: 0,58-0,81) y el historial de asma (RR = 0,66; IC 95%: 0,47-0,95) mostraron efectos protectores frente a la muerte atribuible a la gripe. La ventilación mecánica causó el mayor aumento del riesgo de muerte (RR = 3,31; IC 95%: 2,89-3,79). También se asoció a una mayor letalidad hospitalaria por gripe el hecho de ser hombre, tener edad avanzada, el subtipo AH1N1 y otras enfermedades crónicas. Conclusiones Nuestros hallazgos recalcan la gran importancia de fomentar la inmunización de individuos de alto riesgo, a la vez que se asegura un tratamiento antiviral temprano y eficaz en los casos sospechosos de gripe (AU)
Objective To identify factors associated with the risk of death in adolescent and adult inpatients with laboratory-positive (reverse-transcription polymerase chain reaction) influenza in Mexico during consecutive influenza seasons (2018-2020). Patients and methods A retrospective cohort study used national surveillance system data, enrolling 3422 individuals. The association between various risk factors and 30-day in-hospital lethality were evaluated through risk ratios (RR) and 95% confidence intervals (CI). Results The lethality rate was 18.1%. Flu vaccination history (RR = 0.56, 95% CI 0.42-0.78), early antiviral drug administration (≤ two days from symptom onset [reference ≥ 5 days], RR = 0.68, 95% CI 0.58-0.81), and a history of asthma (RR = 0.66, 95% CI 0.47-0.95) showed protective effects against influenza-attributable death. Mechanical ventilator support produced the highest increase in death risk (RR = 3.31, 95% CI 2.89-3.79). Male sex, older age, AH1N1 subtype, and other chronic diseases were also associated with fatal in-hospital influenza-related outcomes. Conclusions Our findings highlight the major relevance of promoting immunization in high-risk individuals, together with ensuring early and effective antiviral management in suspected influenza cases (AU)
Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Mortalidad Hospitalaria , Gripe Humana/mortalidad , Gripe Humana/terapia , Estudios Retrospectivos , Estudios de Cohortes , Factores de Riesgo , México/epidemiologíaRESUMEN
Resumen OBJETIVO: Determinar las diferencias morfológicas macro y microscópicas en las placentas de pacientes con preeclampsia o restricción del crecimiento intrauterino con las de pacientes sanas. MATERIALES Y MÉTODOS: Estudio de casos y controles, retrospectivo, observacional y comparativo. Se revisaron las bases de datos del servicio de Medicina Materno Fetal del Instituto Nacional de Perinatología (INPer) de febrero de 2018 a marzo de 2020 en busca de pacientes con embarazo único y diagnóstico de preeclampsia temprana o restricción del crecimiento temprano y finalización del embarazo en el INPer. El análisis de los datos se llevó a cabo en el programa estadístico SPSS versión 25. Las variables categóricas se compararon entre grupos con χ2 y los resultados se representaron en porcentajes. Para la evaluación estadística analítica se utilizó ANOVA para una muestra independiente para contrastar las asociaciones entre las diversas variables. RESULTADOS: Se incluyeron 52 pacientes que se dividieron en: grupo 1: preeclampsia temprana sin restricción del crecimiento intrauterino (n = 13), grupo 2: preeclampsia y restricción del crecimiento intrauterino temprano (n = 13), grupo 3: restricción del crecimiento intrauterino temprano (n = 13) y grupo 4 (control) pacientes sanas (n = 13). Se demostró una diferencia estadísticamente significativa en el peso de la placenta, con un valor de p < 0.05 pero sin diferencia en el diámetro del cordón umbilical entre los cuatro grupos. CONCLUSIONES: El estudio histopatológico placentario es una oportunidad para obtener información detallada de la base fisiopatológica de la enfermedad y, así, ofrecer una asesoría y seguimiento preciso a la paciente y al neonato.
Abstract OBJECTIVE: To determine the macro and microscopic morphologic differences in placentas of patients with preeclampsia or intrauterine growth restriction with those of healthy patients. MATERIALS AND METHODS: A retrospective, observational and comparative case-control study. The databases of the Maternal Fetal Medicine service of the National Institute of Perinatology (INPer) from February 2018 to March 2020 were reviewed for patients with singleton pregnancy and diagnosis of early preeclampsia or early growth restriction and termination of pregnancy at the INPer. Data analysis was performed in the statistical program SPSS version 25. Categorical variables were compared between groups with χ2 and the results were represented in percentages. For the analytical statistical evaluation, ANOVA for an independent sample was used to contrast the associations between the various variables. RESULTS: Fifty-two patients were included and divided into: group 1: early preeclampsia without intrauterine growth restriction (n = 13), group 2: preeclampsia and early intrauterine growth restriction (n = 13), group 3: early intrauterine growth restriction (n = 13) and group 4 (control) healthy patients (n = 13). A statistically significant difference in placental weight was demonstrated, with a p value < 0.05 but no difference in umbilical cord diameter among the four groups. CONCLUSIONS: Placental histopathologic study is an opportunity to obtain detailed information on the pathophysiologic basis of the disease and thus provide accurate counseling and follow-up to the patient and neonate.